COMBACTE-CDI

Combatting Bacterial Resistance in Europe - Clostridium Difficile Infections
COMBACTE-CDI logo

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 9
Grant agreement number
777362

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
2 312 305
EFPIA in kind
2 269 913
Total Cost
4 582 218

Summary

Clostridium difficile infection (CDI) is one of the most common healthcare-associated infections, with 172 000 cases annually, many of them in the elderly, in Europe alone. Symptoms include diarrhoea and abdominal pain, and it can prove fatal. Despite its immense impact on patients and healthcare systems, researchers lack a good understanding of the epidemiology and clinical impact of CDI across Europe. The goal of the COMBACTE-CDI project is to change that, by delivering extensive data on the extent and impact of CDI across all healthcare sectors in Europe. This information is essential for the development of better methods to prevent and treat CDI.

A large part of the project is devoted to a large epidemiology study which will quantify the burden of CDI (including incidence, distribution, recurrence, mortality, and transmission) across the whole healthcare economy. The project will also assess current practices on the management of CDI in Europe (including guidelines, testing, surveillance, treatment, and costs) and their potential impacts. Finally, the project will create a pan-European research platform capable of supporting future proof-of-concept and clinical studies of new prevention and treatment strategies for CDI.

In the long term, the knowledge generated by COMBACTE-CDI will aid the development of better strategies to prevent and treat this deadly infection.

Participants Show participants on map

EFPIA companies
  • Astrazeneca AB, Södertälje, Sweden
  • Biomerieux SA, Marcy L'Etoile, France
  • Da Volterra SAS, Paris, France
  • Glaxosmithkline Biologicals SA, Rixensart, Belgium
  • Pfizer Limited, Sandwich, Kent , United Kingdom
  • Sanofi Pasteur SA, Lyon, France
Universities, research organisations, public bodies, non-profit groups
  • Academisch Ziekenhuis Leiden, Leiden, Netherlands
  • Eberhard Karls Universitaet Tuebingen, Tuebingen, Germany
  • Istituto Nazionale Per Le Malattie Infettive Lazzaro Spallanzani-Istituto Di Ricovero E Cura A Carattere Scientifico, Rome, Italy
  • Klinikum Der Universitaet Zu Koeln, Cologne, Germany
  • Nacionalni Laboratorij Za Zdravje, Okolje In Hrano, Maribor, Slovenia
  • Universitair Medisch Centrum Utrecht, Utrecht, Netherlands
  • Universiteit Antwerpen, Antwerp, Belgium
  • University Of Leeds, Leeds, United Kingdom

CONTACT

Project coordinator
Marc JM BONTEN
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
mbonten[at]umcutrecht.nl
Project leader
Charles KNIRSCH
PFIZER
Charles.Knirsch[at]pfizer.com